Author
Fereshteh Chekin
Recent research
- Health & Medicine
Background: Imatinib (IM) is a tyrosine kinase inhibitor that targets the growth factor receptors. IM has demonstrated remarkable clinical efficacy across multiple cancer types. IM abrogates the activity of the Bcr-Abl oncoprotein, leading to the inhibition of cell proliferation...